Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 650, doi. 10.1007/s10637-022-01219-5

By:

• Wu, Jing-Jing;
• Wang, Wen-Hua;
• Dong, Meng;
• Ma, Shan-Shan;
• Zhang, Xu-Dong;
• Zhu, Li-Nan;
• Niu, Song-Tao;
• Ding, Meng-Jie;
• Zhang, Jie-Ming;
• Zhang, Lei;
• Li, Xin;
• Li, Ling;
• Sun, Zhen-Chang;
• Wang, Xin-Hua;
• Fu, Xiao-Rui;
• Li, Zhao-Ming;
• Chang, Yu;
• Nan, Fei-Fei;
• Yan, Jia-Qin;
• Yu, Hui

Publication type:

Article